Immunization with a Hemagglutinin-Derived Synthetic Peptide Formulated with a CpG-DNA-Liposome Complex Induced Protection against Lethal Influenza Virus Infection in Mice

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Rhee, Jae Won ^a   Kim, Dongbum ^a   Park, Byung Kwon ^a   Kwon, Sanghoon ^a   Cho, Sunhee ^a   Lee, Ilseob ^a   Park, Man Seong ^a   Seo, Jae Nam ^a   Kim, Yong Sun ^a   Choi, Hong Seok ^a   Lee, Younghee ^b   Kwon, Hyung Joo ^a  

^a Hallym University   (South Korea)

^b Chungbuk National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DNA; EPITOPE; IMMUNOGLOBULIN G; INFLUENZA VIRUS HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ VACCINE; LIPOPLEX; PEPTIDE VACCINE; PHOSPHODIESTERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ANTIGEN STRUCTURE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG STRUCTURE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; INFLUENZA A; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; VIRUS LOAD;

AMINO ACID SEQUENCE; ANIMALS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LIPOSOMES; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OLIGODEOXYRIBONUCLEOTIDES; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN STRUCTURE, TERTIARY;

MUS; ORTHOMYXOVIRIDAE;

EID: 84868681252     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048750     Document Type: Article

References (60)

1. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
2. Centers for Disease Control and Prevention (CDC) (1997) Isolation of avian influenza A (H5N1) viruses from humans-Hong Kong, May-December 1997. MMWR Morb Mortal Wkly Rep 46: 1204-1207.
3. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, et al. (2008) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358: 261-273 (2008).
4. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, et al. (2004) Avian influenza virus A (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A 101: 1356-1361.
5. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, et al. (1999) Human infection with influenza H9N2. Lancet 354: 916-917.
6. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, et al. (2005) Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 352: 333-340.
7. WHO (2008) Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2008_06_19/en/index.html.
8. Peiris JS, de Jong MD, Guan Y, (2007) Avian influenza virus (H5N1): a threat to human health. Clin Microbial Rev 20: 243-267.
9. Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, et al. (2006) Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 194: 1032-1039.
10. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, et al. (1999) Rescue of influenza A virus from recombinant DNA. J Virol 73: 9679-9682.
11. Maassab HF, Bryant ML, (1999) The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol 9: 237-244.
12. Stech J, Garn H, Wegmann M, Wagner R, Klenk HD, (2005) A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutin. Nat Med 11: 683-689.
13. Steel J, Lowen AC, Pena L, Angel M, Solórzano A, et al. (2009) Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 83: 1742-1753.
14. Mueller S, Coleman JR, Papamichail D, Ward CB, Nimnual A, et al. (2010) Live attenuated influenza virus vaccines by computer-aided rational design. Nat Biotechnol 28: 723-726.
15. Ghendon YZ, Markushin SG, Akopova II, Koptiaeva IB, Nechaeva EA, et al. (2005) Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine. Vaccine 23: 4678-4684.
16. Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, et al. (2008) A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358: 2573-2584.
17. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, et al. (2001) Safety and immunogenicity of a recombinant hamagglutinin vaccine for H5 influenza in humans. Vaccine 19: 1732-1737.
18. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, et al. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749.
19. Chen MW, Cheng TJ, Huang Y, Jan JT, Ma SH, et al. (2008) A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A 105: 13583-13543.
20. Ben-Yedidia T, Arnon R, (2007) Epitope-based vaccine against influenza. Expert Rev Vaccines 6: 939-948.
21. Kaverin NV, Rudneva IA, Govorkova EA, Timofeeva TA, Shilov AA, et al. (2007) Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol 81: 12911-12917.
22. Wang TT, Tan GS, Hai R, Pica N, Ngai L, et al. (2010) Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 107: 18979-18984.
23. Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A, (2007) Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci U S A 104: 246-251.
24. Wang M, Lamberth K, Harndahl M, Røder G, Stryhn A, et al. (2007) CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine 25: 2823-2831.
25. Jeon SH, Ben-Yedidia T, Arnon R, (2002) Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine 20: 2772-2780.
26. Ernst WA, Kim HJ, Tumpey TM, Jansen AD, Tai W, et al. (2006) Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24: 5158-5168.
27. Nagata T, Toyota T, Ishigaki H, Ichihashi T, Kajino K, et al. (2007) Peptides coupled to the surface of a kind of liposome protect infection of influenza viruses. Vaccine 25: 4914-4921.
28. Klinman DM, Currie D, Gursel I, Verthelyi D, (2004) Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 199: 201-216.
29. Lee KW, Jung J, Lee Y, Kim TY, Choi SY, et al. (2006) Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol Immunol 43: 2107-2118.
30. Kim D, Rhee JW, Kwon S, Sohn WJ, Lee Y, et al. (2009) Immunostimulation and anti-DNA antibody production by backbone modified CpG-DNA. Biochem Biophys Res Commmun 379: 362-367.
31. Kim D, Kwon HJ, Lee Y, (2011) Activation of Toll-like receptor 9 and production of epitope specific antibody by liposome-encapsulated CpG-DNA. BMB Rep 44: 607-612.
32. Kim D, Kwon S, Rhee JW, Kim KD, Kim YE, et al. (2011) Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol 12: 29.
33. Kwon S, Kim D, Park BK, Cho S, Kim KD, et al. (2012) Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without cacciers. PLoS ONE 7: e33121.
34. Wilson IA, Skehel JJ, Wiley DC, (1981) Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289: 366-373.
35. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
36. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: e3942.
37. Prabhu N, Prabakaran M, Ho HT, Velumani S, Qiang J, et al. (2009) Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J Virol 83: 2553-2562.
38. Jiang T, Zhao H, Li XF, Deng YQ, Liu J, et al. (2011) CpG oligodeoxynucleotides protect against the 2009 H1N1 pandemic influenza virus infection in a murine model. Antiviral Res 89: 124-126.
39. Wong JP, Christopher ME, Viswanathan S, Karpoff N, Dai X, et al. (2009) Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 27: 3481-3483.
40. Ben-Yedidia T, Arnon R, (1997) Design of peptide and polypeptide vaccines. Curr Opin Biotechnol 8: 442-448.
41. Bijker MS, Melief CJ, Offringa R, van der Burg SH, (2007) Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 6: 591-603.
42. Castilow EM, Olson MR, Varga SM, (2007) Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res 39: 225-239.
43. Stein CA, Subasinghe C, Shinozuka K, Cohen JS, (1988) Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 16: 3209-3221.
44. Zhao Q, Waldschmidt T, Fisher E, Herrera CJ, Krieg AM, (1994) Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. Blood 84: 3660-3666.
45. Krieg AM, (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5: 471-484.
46. Deng GM, Nilsson IM, Verdrengh M, Collins LV, Tarkowski A, (1999) Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med 5: 702-705.
47. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, et al. (2004) Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 10: 187-192.
48. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE, (1996) Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest 98: 1119-1129.
49. Oh HL, Akerström S, Shen S, Bereczky S, Karlberg H, et al. (2010) An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses. J Virol 84: 8275-8286.
50. Edwards MJ, Dimmock NJ, (2001) A haemagglutinin (HA1)-specific FAb neutralizes influenza A virus by inhibiting fusion activity. J Gen Virol 82: 1387-1395.
51. Imai M, Sugimoto K, Okazaki K, Kida H, (1998) Fusion of influenza virus with the endosomal membrane is inhibited by monoclonal antibodies to defined epitopes on the hemagglutinin. Virus Res 53: 129-139.
52. Parker JM, Hodges PC, (1986) New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and x-ray-derived accessible sites. Biochemistry 25: 5425-5432.
53. Emini EA, Hughes JV, Perlow DS, Boger J, (1985) Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 55: 836-839.
54. Chou PY, Fasman GD, (1978) Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol 47: 45-148.
55. Kolaskar AS, Tongaonkar PC, (1990) A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 276: 172-174.
56. Gregoriadis G, Saffie R, Hart SL, (1996) High yield incorporation of plasmid DNA within liposomes: Effect on DNA integrity and transfection efficiency. J Drug Target 3: 469-475.
57. Hoffmann E, Krauss S, Perez D, Webby R, Webster RG, (2002) Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20: 3165-3170.
58. Kida H, Brown LE, Webster RG, (1982) Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Ser/Massachusetts1/80(H7N7) influenza virus. Virology 122: 38-47.
59. Reed LJ, Muench H, (1938) A simple method for estimating fifty percent endpoints. Am J Epidemiol 27: 493-497.
60. Cohen A, Newland SE, Biddlef, (1963) Inhibition of influenza virus haemagglutination: a difference of behavior in sera from a single species. Virology 20: 518-529.